The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.
April 22nd 2024
Efficacy results support long-term use of risankizumab in patients with active psoriatic arthritis across multiple patient and psoriatic disease characteristics.
Therapeutic Advances in Plaque Psoriasis to Address Unmet Needs in Treatment and Improve Patient Outcomes
1.5 Credits / Dermatology
View More
Managed Care Considerations for Management of Molluscum Contagiosum: Examining Emerging Treatments
1.0 Credit / Dermatology
View More
AJMC® Powered by Patients and Managed Care Insights – More Than a Cosmetic Disease: Vitiligo Treatment Approaches and Raising Awareness of the Disease Burden
1.5 Credits / Dermatology
View More
Women Report Greater Psoriasis QOL Impact, Reduced Treatment Satisfaction With Biologics
June 6th 2022Efficacy of biologics was observed in both men and women with psoriasis, although female patients reported a greater impact from the disease on quality of life (QOL) and lower treatment satisfaction.
Read More
Psoriasis May Increase Risk of Ectopic Pregnancy, a Driver of Maternal Morbidity
June 2nd 2022Risk of ectopic pregnancy, the leading cause of maternal morbidity and mortality in the first trimester of pregnancy, was significantly associated with psoriasis in Danish women, especially those with moderate to severe disease.
Read More
Real-world Efficacy of Risankizumab in Psoriasis Shown for Patients With Prior Biologic Failure
May 28th 2022Real-world patients with moderate to severe plaque psoriasis who had experienced prior biologic failure demonstrated significant improvement and an adequate safety profile with risankizumab treatment.
Read More
Greater Biologic Persistence, Adherence Achieved With Ixekizumab for Psoriasis
May 16th 2022Significantly greater persistence, adherence, and time on monotherapy was achieved with the use of ixekizumab vs the biologics adalimumab, etanercept, secukinumab, and ustekinumab, in the treatment of moderate to severe psoriasis.
Read More
Study Finds Bimekizumab Well Tolerated Long Term for Moderate to Severe Psoriasis
May 11th 2022Bimekizumab demonstrated a favorable long-term safety profile for the treatment of moderate to severe psoriasis, aside from an increased incidence of mild to moderate oral candidiasis that was also observed with short-term exposure.
Read More
Overlapping Comorbidity Risks Found in Patients With Plaque Psoriasis, Palmoplantar Pustulosis
May 5th 2022An overlapping comorbidity profile was observed among patients with plaque psoriasis and palmoplantar pustulosis, although risks of certain comorbid conditions varied between the 2 groups.
Read More
Cardiovascular Risk Significantly Greater in Patients With Psoriatic Disease
May 2nd 2022A significantly greater risk of cardiovascular events was observed among a multiethnic Brazilian population of patients with psoriasis and psoriatic arthritis vs controls, in which those in the sixth decade of life had the highest risk.
Read More
Dr Stephen Rozzo Discusses Real-world Efficacy of Tildrakizumab for Psoriasis
April 22nd 2022Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, discussed findings of 2 phase 4 real-world studies on tildrakizumab, which showed that patients achieved significant improvement in severity and quality of life by week 4 of treatment.
Watch
Ixekizumab Effective Long-term for Treatment of Psoriasis in Pediatric Patients
April 20th 2022Pediatric patients with psoriasis exhibited significant improvements in self-reported outcomes and objective measures of complete skin clearance when treated with ixekizumab vs placebo, with no new safety findings identified.
Read More
Dr Stephen Rozzo Explains Real-world Study Design for Tildrakizumab in Psoriasis
April 15th 2022Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, spoke on the design of the 2 phase 4 real-world studies investigating severity and quality of life impact of tildrakizumab for the treatment of psoriasis.
Watch
Dr Stephen Rozzo on Regulatory Nature of Tildrakizumab for Psoriasis
April 7th 2022Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, explains tildrakizumab’s mechanisms of action in the treatment of psoriasis and how the drug differs from other approved biologics.
Watch
Examining the Impact of Psoriasis Disease Burden on QOL, Mental Health
April 4th 2022Two abstracts presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting explored the health-related quality of life (QOL) and mental health impact of psoriasis disease burden by severity and affected body region.
Read More
Greater Biologic Retention Found With IL-17 vs TNF Inhibitors For Psoriasis, PsA
March 30th 2022Longer drug survival was associated with interleukin-17 (IL-17) inhibitors vs tumor necrosis factor (TNF) inhibitors in the treatment of psoriasis and psoriatic arthritis, but persistence rates for first-line biologics overall remained low.
Read More
Dr Soumya Chakravarty Discusses Impact of Diagnostic Delays for Psoriatic Arthritis
March 11th 2022Soumya Chakravarty, MD, PhD, FACP, FACR, strategic lead, Rheumatology Therapeutic Area at Janssen, spoke on adverse patient outcomes caused by diagnostic delays in psoriatic arthritis and progress made to address this unmet need.
Read More
Dr Soumya Chakravarty on Intertwined Pathophysiology of Psoriasis, Psoriatic Arthritis
March 2nd 2022Soumya Chakravarty, MD, PhD, FACP, FACR, strategic lead of the Rheumatology Therapeutic Area at Janssen, discussed the interlinked pathophysiology of psoriasis and psoriatic arthritis, and the involvement of inflammatory mediators for both conditions.
Watch
Dr Edward W. Cowen on Unmet Needs, Care Considerations Regarding Pustular Psoriasis
February 26th 2022Edward W. Cowen, MD, MHSc, senior clinician and acting branch chief, Dermatology Branch, National Institutes of Health, discusses considerations to address unmet needs and identify appropriate treatment of patients with pustular psoriasis.
Read More